



08-31-07

IFW

Dkt. No. 96700/1139

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**


Applicants : Geroge J. Christ, Kelvin Davies, and Arnold Melman  
Appl. No. : 10/579,705 (§371 of PCT/US2004/039308)  
Filed : May 18, 2006  
For : GENE TRANSFER FOR REGULATING SMOOTH MUSCLE TONE  
Art Unit : Not yet assigned  
Examiner : Not yet assigned  
Customer No.: 1912

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

"Express Mail" mailing label No. EV 725836867 US  
Date of Deposit: August 30, 2007

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Name: Alan D. Miller  
Signature: 

Sir:

This Supplemental Information Disclosure Statement is being filed to supplement the Information Disclosure Statement filed on May 18, 2006 in connection with the above-identified application.

In accordance with the duty of disclosure under 37 C.F.R. §1.56, applicants would like to direct the Examiner's attention to the seven references that are listed on enclosed Form PTO/SB/08A-B (2 pages). A copy of each non-U.S. patent reference is attached hereto.

Applicants: George J. Christ et al.

Appl'n. No.: 10/579,705

Filed: May 18, 2006

Page 2


The non-U.S. patent references were cited in a Supplementary Partial European Search Report issued in connection with counterpart European Patent Application No. 04811938.2. A copy of the Search Report is also enclosed (5 pages).

Applicants are submitting the subject Supplemental Information Disclosure Statement pursuant to 37 C.F.R. §1.97(b)(3) before the mailing of a first Office Action on the merits. Accordingly, no fee is deemed necessary in connection with the filing of this Supplemental Information Disclosure Statement. However, if any fee is required in connection with the submission of this Supplemental Information Disclosure Statement or to maintain the pendency of the subject application, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 01-1785.


Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN LLP  
Attorneys for Applicants  
90 Park Avenue  
New York, New York 10016  
(212) 836-8000

By \_\_\_\_\_

  
Alan D. Miller, Reg. No. 42,889

Dated: August 30, 2007  
New York, New York



PTO/SB/08A (04-07)

Approved for use through 09/30/2007. OMB 0651-0031

**U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE**

**Substitute for form 1449/PTO**

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

**(Use as many sheets as necessary)**

Sheet

1

of

2

**Complete if Known**

Application Number	10/579,705
Filing Date	May 18, 2006
First Named Inventor	George J. Christ
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	96700/1139

## **U. S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

2

of

2

**Complete if Known**

Application Number	10/579,705
Filing Date	May 18, 2006
First Named Inventor	George J. Christ
Art Unit	Not yet assigned
Examiner Name	Not yet assigned

Attorney Docket Number

96700/1139

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	2	BRENDEL J et al., entitled "Blockers of the Kv1.5 channel for the treatment of atrial arrhythmias," Expert Opinion on Therapeutic Patents, Vol. 12, No. 11, November 1, 2002, pp. 1589-1598.	
	3	COGAN J G et al., entitled "Plasticity of Vascular Smooth Muscle Alpha-Actin Gene Transcription. Characterization of Multiple, Single-, and Double-Strand Specific DNA-Binding Proteins in Myoblasts and Fibroblasts," Journal of Biological Chemistry, Vol. 270, No. 19, May 12, 1995, pp. 11310-11321.	
	4	ARCHER S L, entitled "Potassium Channels and Erectile Dysfunction," Vascular Pharmacology, Vol. 38, January 2002, pp. 61-71.	
	5	RO S et al., entitled "Molecular properties of small-conductance Ca <sup>2+</sup> -activated K <sup>+</sup> channels expressed in murine colonic smooth muscle," Am J Physiol Gastrointest Liver Physiol, October 2001, Vol. 281, No. 4, pp. G964-G973.	
	6	HERRERA G M et al, entitled "Differential regulation of SK and BK channels by Ca <sup>2+</sup> signals from Ca <sup>2+</sup> channels and ryanodine receptors in guinea-pig urinary bladder myocytes," The Journal of Physiology, June 1, 2002, Vol. 541, No. Pt 2, pp. 483-492.	
	7	CHRIST G J et al., entitled "Intracorporal injection of hSlo cDNA in rats produces physiologically relevant alterations in penile function," The American Journal of Physiology, Vol. 275, No. 2, Part 2, August 1998, pp. H600-H608.	
	8	MELMAN A et al., entitled "The Successful Long-Term Treatment of Age Related Erectile Dysfunction With HSlo cDNA in Rats in Vivo," Journal of Urology, Vol. 170, No. 1, July 2003, pp. 285-290.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:  
**Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.